A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between Florbetapir (18F) PET status and cognitive decline.
Phase of Trial: Phase III
Latest Information Update: 23 Aug 2016
Price : $35 *
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 22 Jul 2015 According to an Eli Lily media release, data from this study were presented today at the Alzheimer's Association International Conference 2015 (AAIC).
- 22 Jul 2015 Results published in an Eli Lily media release.
- 30 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov